I-Mab
I-Mab (IMAB) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for I-Mab (IMAB), featuring income statements, balance sheets, and cash flow data.
I-Mab (IMAB) Income Statement & Financial Overview
Review I-Mab IMAB income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $777000.00 | $6.03M | $4.47M | $22.80M |
| SG&A Expenses | $4.49M | $7.34M | $7.94M | $11.87M |
| Operating Expenses | $5.27M | $13.37M | $12.41M | $15.008M |
| Total Costs & Expenses | $5.27M | $13.37M | $12.41M | $15.008M |
| Interest Income | $1.87M | $2.20M | $2.45M | $1.92M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $0.00 | $0.00 | $5.99M |
| EBITDA | -$5.27M | -$12.10M | -$12.41M | -$15.008M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$5.27M | -$13.37M | -$12.41M | -$15.008M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $2.12M | $2.53M | -$8.08M | -$34.48M |
| Income Before Tax | -$3.15M | -$10.84M | -$20.49M | -$49.49M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$42.68M |
| Net Income | -$3.15M | -$9.06M | -$20.49M | $25.13M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.05 | -$0.11 | -$0.25 | $0.31 |
| Diluted EPS | -$0.05 | -$0.11 | -$0.25 | $0.31 |
| Weighted Avg Shares Outstanding | $81.60M | $81.50M | $81.50M | $81.78M |
| Weighted Avg Shares Outstanding (Diluted) | $81.60M | $81.50M | $81.50M | $80.93M |
Over the past four quarters, I-Mab demonstrated steady revenue growth, increasing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Operating income reached -$5.27M in Q1 2025, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$5.27M, reflecting operational efficiency. Net income rose to -$3.15M, with EPS at -$0.05. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan